Evaluation of FGF-19 and β-klotho as biomarkers in patients with intrahepatic cholestasis of pregnancy.
CYP7A1
fibroblast growth factor-19
intrahepatic cholestasis of pregnancy
pathogenesis
β-klotho
Journal
Archives of medical science : AMS
ISSN: 1734-1922
Titre abrégé: Arch Med Sci
Pays: Poland
ID NLM: 101258257
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
18
11
2017
accepted:
19
12
2017
entrez:
31
1
2019
pubmed:
31
1
2019
medline:
31
1
2019
Statut:
ppublish
Résumé
Fibroblast growth factor-19 (FGF-19) and its co-receptor, beta-klotho, regulate bile acid synthesis in the liver as an enterohepatic feedback mechanism. In this study, our aim was to investigate the circulating FGF-19 and β-klotho levels in intrahepatic cholestasis of pregnancy (ICP) cases. A cross-sectional study including 40 women whose pregnancies were complicated with ICP were recruited for the study group. Forty randomly selected healthy pregnant women comprised the control group. The patient characteristics, including maternal age, gravidity, parity, gestational age at the time of diagnosis, body mass index (BMI), and obstetric history, were recorded. The serum FGF-19 and β-klotho concentrations were measured using an enzyme-linked immunosorbent assay. Maternal age, gravidity, parity, body mass index at assessment, and gestational age at blood sampling were similar between the two groups ( The serum FGF-19 and β-klotho concentrations did not differ between the pregnancies with ICP and the healthy controls. However, in some cases, abnormalities in the FGF-19, β-klotho, and FGFR4 signaling system may play roles in the pathogenesis of ICP.
Identifiants
pubmed: 30697260
doi: 10.5114/aoms.2017.72424
pii: 31370
pmc: PMC6348354
doi:
Types de publication
Journal Article
Langues
eng
Pagination
113-119Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Biol Chem. 2000 May 19;275(20):15482-9
pubmed: 10809780
Clin Liver Dis. 1999 Aug;3(3):603-32
pubmed: 11291241
Genes Dev. 2003 Jul 1;17(13):1581-91
pubmed: 12815072
J Clin Invest. 2005 Aug;115(8):2202-8
pubmed: 16075061
Cell Metab. 2005 Oct;2(4):217-25
pubmed: 16213224
Hepatology. 2006 Apr;43(4):723-8
pubmed: 16557542
J Biol Chem. 2007 Sep 14;282(37):27277-84
pubmed: 17627937
Gastroenterology. 2007 Aug;133(2):507-16
pubmed: 17681172
J Biol Chem. 2007 Oct 5;282(40):29069-72
pubmed: 17711860
Dig Dis Sci. 2008 Sep;53(9):2334-58
pubmed: 18256934
Expert Rev Mol Med. 2008 Mar 28;10:e9
pubmed: 18371245
Trends Endocrinol Metab. 2008 Sep;19(7):239-45
pubmed: 18692401
Hepatology. 2009 Apr;49(4):1228-35
pubmed: 19185005
Lancet. 2010 Feb 13;375(9714):594-605
pubmed: 20159293
Cell Metab. 2012 Dec 5;16(6):693-705
pubmed: 23217254
Hepatology. 2014 Apr;59(4):1482-91
pubmed: 23857305
World J Gastroenterol. 2013 Nov 21;19(43):7639-46
pubmed: 24282353
Am J Gastroenterol. 2014 Jan;109(1):76-84
pubmed: 24366234
Obstet Gynecol. 2014 Jul;124(1):120-33
pubmed: 24901263
Wiley Interdiscip Rev Dev Biol. 2015 May-Jun;4(3):215-66
pubmed: 25772309
J Hepatol. 2015 Apr;62(1 Suppl):S25-37
pubmed: 25920087
Dig Dis. 2015;33(3):327-31
pubmed: 26045265
Sci Rep. 2015 Aug 21;5:13462
pubmed: 26293907
J Matern Fetal Neonatal Med. 2018 Aug;31(15):2066-2070
pubmed: 28552021
PLoS One. 2017 Jun 1;12(6):e0178580
pubmed: 28570655
Arch Med Sci. 2017 Jun;13(4):753-759
pubmed: 28721142
J Matern Fetal Neonatal Med. 2017 Dec 12;:1-6
pubmed: 29233036
Arch Med Sci. 2018 Jun;14(4):846-850
pubmed: 30002703
Hepatology. 1997 Aug;26(2):358-64
pubmed: 9252146